Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.

van Damme, Pierre and Kafeja, Froukje and Anemona, Alessandra and Basile, Venere and Hilbert, Anne Katrin and De Coster, Ilse and Rondini, Simona and Micoli, Francesca and Qasim Khan, Rana M and Marchetti, Elisa and Di Cioccio, Vito and Saul, Allan and Martin, Laura B and Podda, Audino (2011) Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PloS one, 6 (9). e25398. ISSN 1932-6203

Abstract

Typhoid fever causes more than 21 million cases of disease and 200,000 deaths yearly worldwide, with more than 90% of the disease burden being reported from Asia. Epidemiological data show high disease incidence in young children and suggest that immunization programs should target children below two years of age: this is not possible with available vaccines. The Novartis Vaccines Institute for Global Health developed a conjugate vaccine (Vi-CRM₁₉₇) for infant vaccination concomitantly with EPI vaccines, either starting at 6 weeks with DTP or at 9 months with measles vaccine. We report the results from a Phase 1 and a Phase 2 dose ranging trial with Vi-CRM₁₉₇ in European adults.

Item Type: Article
Related URLs:
Related URLs:
Date Deposited: 13 Oct 2015 13:14
Last Modified: 13 Oct 2015 13:14
URI: https://oak.novartis.com/id/eprint/6437

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.